Albert Saporta

Stallergenes SA is an international biopharmaceutical company, which engages in the manufacture and sale of pharmaceutical products for the treatment of allergy-related respiratory diseases. The company operates through the Allergen Immunotherapy segment, which provides products and services for the desensitization of allergy-related respiratory conditions. Its products include a range of sublingual route and subcutaneous route products for the treatment of respiratory diseases such as rhino-conjunctivitis, rhinitis, and allergic asthma. Stallergenes was founded in 1962 and is headquartered in Antony, France.

Alternative Investment Management & Research SA (AIM&R) is an alternative research and investment management firm which was founded in 1995 by Albert Saporta. Located in Geneva, Switzerland, AIM&R manages the S.O.G. Fund and SOGAsia hedge funds and managed accounts for sophisticated investors. In 2003 the firm formed a strategic alliance with United Overseas Bank Ltd., Singapore, through their subsidiary UOB Global Capital LLC, for the exclusive worldwide distribution of the SOGAsia Fund. AIM&R also advises hedge funds and trading groups.

Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France.

Stallergènes Belgium NV manufactures pharmaceutical products used for the treatment of allergies. It produces desensitization products and treatment for allergies. The firm has offices in Belgium, Czech Republic, Germany, Spain, France, Italy, the Netherlands, Austria, Poland, Portugal, and Slovenia. The company was founded in 1962 and is headquartered in Waterloo, Belgium.